Policosanol Attenuates Statin-Induced Increases in Serum Proprotein Convertase Subtilisin/Kexin Type 9 When Combined with Atorvastatin

Figure 2

Effect of policosanol on serum lipid levels. (a) In Protocol I, serum low-density lipoprotein cholesterol levels decreased significantly at 8 weeks compared with baseline in both treatment groups (both , shown as “∗”). (b) In contrast with Protocol I, serum low-density lipoprotein cholesterol levels did not decrease significantly even at 12 weeks compared with baseline in both treatment groups in Protocol II (both ). (c) In Protocol I, the extent of the low-density lipoprotein cholesterol decrease between the atorvastatin group and the policosanol + atorvastatin group was not statistically significant (−38.5% versus −35.3%, ). Similarly, in Protocol II, the change of the low-density lipoprotein cholesterol between the policosanol group and control group was not statistically significant (1.1% versus 2.7%, ).

(a)

(b)

(c)